ADC Therapeutics SA (ADCT)

The investment case here is defined by a stark disconnect between the company's deteriorating operational reality and the market's lingering hope for a turnaround. Fundamentally, the business is in distress: it is burning cash aggressively with negative free cash flow and operating margins, while the stock has erased nearly 87% of its value over the last five years. Although the most recent annual report shows a rebound in price, the underlying fundamentals—negative book value and shrinking revenues—do not support a 'buy and hold' thesis. The recent news of patient deaths in clinical trials adds a layer of specific execution risk that makes the path to profitability even steeper. However, the short-term outlook is driven entirely by speculation rather than value. The options market is screaming for a move higher, with heavy positioning in far-out calls and virtually no protective put writing. This suggests traders are waiting for a binary event, such as a positive clinical reading or a strategic partnership, to ignite a rally. Given the very low reliability of statistical forecasts and the high beta, this is a volatile, high-risk vehicle suitable only for those willing to gamble on a specific catalyst, not a stable investment. The lack of a dividend and the severe capital destruction make it unsuitable for income or conservative capital preservation.